{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:59:05Z","timestamp":1790819945931,"version":"4.1.0"},"reference-count":98,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.jns.2026.126191","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:29:55Z","timestamp":1790263795000},"page":"126191","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["An integrated framework for clinical surveillance in multiple sclerosis: An evidence-informed narrative review"],"prefix":"10.1016","volume":"491","author":[{"given":"Ana Herrero","family":"Valverde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Capela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Comabella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jns.2026.126191_bb0005","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1177\/1352458517751049","article-title":"ECTRIMS\/EAN guideline on the pharmacological treatment of people with multiple sclerosis","volume":"24","author":"Montalban","year":"2018","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.jns.2026.126191_bb0010","first-page":"27","article-title":"KPFL. Monitoring disease course and treatment response in various populations with multiple sclerosis","author":"Valizadeh","year":"2025","journal-title":"Practical Neurology (US)."},{"issue":"8","key":"10.1016\/j.jns.2026.126191_bb0015","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S1474-4422(21)00095-8","article-title":"2021 MAGNIMS\u2013CMSC\u2013NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis","volume":"20","author":"Wattjes","year":"2021","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.jns.2026.126191_bb0020","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1136\/pn-2024-004228","article-title":"Using disease-modifying treatments in multiple sclerosis: Association of British Neurologists (ABN) 2024 guidance","volume":"25","author":"Rashid","year":"2025","journal-title":"Pract. Neurol."},{"issue":"6\u20137","key":"10.1016\/j.jns.2026.126191_bb0025","doi-asserted-by":"crossref","first-page":"414","DOI":"10.20344\/amp.22380","article-title":"Multiple sclerosis disease-modifying treatment algorithms: 2025 positioning of the Portuguese multiple sclerosis study group","volume":"38","author":"Capela","year":"2025","journal-title":"Acta Medica Port."},{"key":"10.1016\/j.jns.2026.126191_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104573","article-title":"Kappa free light chain and neurofilament light independently predict early multiple sclerosis disease activity\u2014a cohort study","volume":"91","author":"Hegen","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jns.2026.126191_bb0035","doi-asserted-by":"crossref","unstructured":"Abdelhak A, Benkert P, Schaedelin S, Boscardin WJ, Cordano C, Oechtering J, et al. Neurofilament light chain elevation and disability progression in multiple sclerosis. JAMA Neurol. 2023 Dec 1;80(12):1317. doi:https:\/\/doi.org\/10.1001\/jamaneurol.2023.3997.","DOI":"10.1001\/jamaneurol.2023.3997"},{"key":"10.1016\/j.jns.2026.126191_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.104970","article-title":"Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management","volume":"101","author":"Freedman","year":"2024","journal-title":"EBioMedicine"},{"issue":"13","key":"10.1016\/j.jns.2026.126191_bb0045","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1177\/1352458518803785","article-title":"Recommendations for cognitive screening and management in multiple sclerosis care","volume":"24","author":"Kalb","year":"2018","journal-title":"Mult. Scler. J."},{"issue":"2","key":"10.1016\/j.jns.2026.126191_bb0050","doi-asserted-by":"crossref","DOI":"10.1212\/CPJ.0000000000200253","article-title":"Practical considerations for managing pregnancy in patients with multiple sclerosis","volume":"14","author":"Graham","year":"2024","journal-title":"Neurol. Clin. Pract."},{"issue":"2","key":"10.1016\/j.jns.2026.126191_bb0055","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000959","article-title":"Clinical and radiologic disease activity in pregnancy and postpartum in MS","volume":"8","author":"Anderson","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"1","key":"10.1016\/j.jns.2026.126191_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40120-022-00421-0","article-title":"Multiple sclerosis in pregnancy: a commentary on disease modification and symptomatic drug therapies","volume":"12","author":"Iyer","year":"2023","journal-title":"Neurol Ther."},{"issue":"8","key":"10.1016\/j.jns.2026.126191_bb0065","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1177\/13524585231168043","article-title":"ECTRIMS\/EAN consensus on vaccination in people with multiple sclerosis: improving immunization strategies in the era of highly active immunotherapeutic drugs","volume":"29","author":"Otero-Romero","year":"2023","journal-title":"Mult. Scler. J."},{"issue":"4","key":"10.1016\/j.jns.2026.126191_bb0070","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1212\/CON.0000000000001140","article-title":"Approach to symptom management in multiple sclerosis with a focus on wellness","volume":"28","author":"Spain","year":"2022","journal-title":"Continuum (N Y)."},{"issue":"9","key":"10.1016\/j.jns.2026.126191_bb0075","doi-asserted-by":"crossref","DOI":"10.1007\/s00415-025-13293-9","article-title":"The use of high-efficacy disease-modifying therapies in multiple sclerosis: recommendations from an expert Delphi consensus","volume":"272","author":"Filippi","year":"2025","journal-title":"J. Neurol."},{"key":"10.1016\/j.jns.2026.126191_bb0080","doi-asserted-by":"crossref","unstructured":"Spelman T, Magyari M, Piehl F, Svenningsson A, Rasmussen PV, Kant M, et al. Treatment escalation vs immediate initiation of highly effective treatment for patients with relapsing-remitting multiple sclerosis. JAMA Neurol. 2021 Oct 1;78(10):1197. doi:https:\/\/doi.org\/10.1001\/jamaneurol.2021.2738.","DOI":"10.1001\/jamaneurol.2021.2738"},{"key":"10.1016\/j.jns.2026.126191_bb0085","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2019.00253","article-title":"Best practices for long-term monitoring and follow-up of alemtuzumab-treated MS patients in real-world clinical settings","volume":"10","author":"Barclay","year":"2019","journal-title":"Front. Neurol."},{"key":"10.1016\/j.jns.2026.126191_bb0090","doi-asserted-by":"crossref","unstructured":"Montalban X, Lebrun-Fr\u00e9nay C, Oh J, Arrambide G, Moccia M, Pia Amato M, et al. Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria. Lancet Neurol. 2025 Oct;24(10):850\u201365. doi:https:\/\/doi.org\/10.1016\/S1474-4422(25)00270-4.","DOI":"10.1016\/S1474-4422(25)00270-4"},{"key":"10.1016\/j.jns.2026.126191_bb0095","series-title":"Optimal clinical care pathway for adults: Multiple Sclerosis","author":"National Neurosciences Advisory Group (NNAG)","year":"2024"},{"issue":"11","key":"10.1016\/j.jns.2026.126191_bb0100","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1001\/jamaneurol.2023.3331","article-title":"Harmonizing definitions for progression independent of relapse activity in multiple sclerosis","volume":"80","author":"M\u00fcller","year":"2023","journal-title":"JAMA Neurol."},{"issue":"2","key":"10.1016\/j.jns.2026.126191_bb0105","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1001\/jamaneurol.2022.4655","article-title":"Association of Early Progression Independent of relapse activity with long-term disability after a first demyelinating event in multiple sclerosis","volume":"80","author":"Tur","year":"2023","journal-title":"JAMA Neurol."},{"issue":"5","key":"10.1016\/j.jns.2026.126191_bb0110","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1093\/brain\/awae409","article-title":"De-escalating and discontinuing disease-modifying therapies in multiple sclerosis","volume":"148","author":"Androdias","year":"2025","journal-title":"Brain"},{"key":"10.1016\/j.jns.2026.126191_bb0115","series-title":"Disease Modifying Therapies in Multiple Sclerosis: National Clinical Recommendations","author":"VA Pharmacy Benefits Management Services; National Formulary Committee","year":"2024"},{"issue":"9","key":"10.1016\/j.jns.2026.126191_bb0120","doi-asserted-by":"crossref","DOI":"10.3390\/biom11091342","article-title":"Measuring treatment response in progressive multiple sclerosis\u2014considerations for adapting to an era of multiple treatment options","volume":"11","author":"Krajnc","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.jns.2026.126191_bb0125","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Expanded disability status scale","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.jns.2026.126191_bb0130","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1177\/1352458509354552","article-title":"Psychometrics and normative data for the multiple sclerosis functional composite: replacing the PASAT with the symbol digit modalities test","volume":"16","author":"Drake","year":"2010","journal-title":"Mult. Scler. J."},{"issue":"12","key":"10.1016\/j.jns.2026.126191_bb0135","doi-asserted-by":"crossref","first-page":"5183","DOI":"10.1007\/s10072-021-05165-7","article-title":"Cognitive impairment in multiple sclerosis: diagnosis and monitoring","volume":"42","author":"Meca-Lallana","year":"2021","journal-title":"Neurol. Sci."},{"issue":"2","key":"10.1016\/j.jns.2026.126191_bb0140","article-title":"A review of the validation of the brief cognitive assessment for multiple sclerosis in Latin America","volume":"11","author":"Jim\u00e9nez-Maldonado","year":"2025","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"10.1016\/j.jns.2026.126191_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2025.106664","article-title":"Migraine and tension-type headache in multiple sclerosis: a two-year, prospective, longitudinal, controlled study","volume":"103","author":"Gklinos","year":"2025","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.jns.2026.126191_bb0150","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1136\/practneurol-2015-001214","article-title":"How to run a multiple sclerosis relapse clinic","volume":"16","author":"Tallantyre","year":"2016","journal-title":"Pract. Neurol."},{"issue":"7","key":"10.1016\/j.jns.2026.126191_bb0155","doi-asserted-by":"crossref","DOI":"10.1007\/s11910-021-01117-y","article-title":"Infection mitigation strategies for multiple sclerosis patients on oral and monoclonal disease-modifying therapies","volume":"21","author":"Smith","year":"2021","journal-title":"Curr. Neurol. Neurosci. Rep."},{"issue":"2","key":"10.1016\/j.jns.2026.126191_bb0160","article-title":"Patient-reported outcome measures in MS: do development processes and patient involvement support valid quantification of clinically important variables","volume":"8","author":"Bharadia","year":"2022","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"issue":"13","key":"10.1016\/j.jns.2026.126191_bb0165","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1177\/13524585251349354","article-title":"The importance of patient-reported outcomes: a call for their integration in the routine care of patients with multiple sclerosis","volume":"31","author":"Cruz Rivera","year":"2025","journal-title":"Mult. Scler. J."},{"issue":"4","key":"10.1016\/j.jns.2026.126191_bb0170","article-title":"Patient-reported outcomes in multiple sclerosis: validation of the quality of life in neurological disorders (neuro-QoL\u2122) short forms","volume":"5","author":"Medina","year":"2019","journal-title":"Mult Scler J Exp Transl Clin."},{"issue":"10","key":"10.1016\/j.jns.2026.126191_bb0175","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/S1474-4422(25)00304-7","article-title":"2024 MAGNIMS\u2013CMSC\u2013NAIMS consensus recommendations on the use of MRI for the diagnosis of multiple sclerosis","volume":"24","author":"Barkhof","year":"2025","journal-title":"Lancet Neurol."},{"issue":"10","key":"10.1016\/j.jns.2026.126191_bb0180","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000210004","article-title":"Associations between paramagnetic rim lesion evolution and clinical and radiologic disease progression in persons with multiple sclerosis","volume":"103","author":"Reeves","year":"2024","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.jns.2026.126191_bb0185","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/s41582-020-0314-x","article-title":"MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice","volume":"16","author":"Sastre-Garriga","year":"2020","journal-title":"Nat. Rev. Neurol."},{"issue":"10","key":"10.1016\/j.jns.2026.126191_bb0190","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1177\/1352458515616701","article-title":"Inclusion of brain volume loss in a revised measure of \u2018no evidence of disease activity\u2019 (NEDA-4) in relapsing\u2013remitting multiple sclerosis","volume":"22","author":"Kappos","year":"2016","journal-title":"Mult. Scler. J."},{"issue":"12","key":"10.1016\/j.jns.2026.126191_bb0195","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.3174\/ajnr.A5876","article-title":"Brain atrophy is associated with disability progression in patients with MS followed in a clinical routine","volume":"39","author":"Ghione","year":"2018","journal-title":"Am. J. Neuroradiol."},{"issue":"1","key":"10.1016\/j.jns.2026.126191_bb0200","first-page":"93","article-title":"Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis","volume":"87","author":"De Stefano","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2026.126191_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanepe.2025.101476","article-title":"The effect of disease-modifying therapies on brain volume loss and disability accumulation in multiple sclerosis: a systematic review and network meta-analysis","volume":"59","author":"Cagol","year":"2025","journal-title":"The Lancet Regional Health - Europe."},{"issue":"5","key":"10.1016\/j.jns.2026.126191_bb0210","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.neubiorev.2013.03.006","article-title":"Localized grey matter atrophy in multiple sclerosis: a meta-analysis of voxel-based morphometry studies and associations with functional disability","volume":"37","author":"Lansley","year":"2013","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"3","key":"10.1016\/j.jns.2026.126191_bb0215","article-title":"The presence of a paramagnetic phase rim in multiple sclerosis is linked to lesion age: an exploratory study","volume":"11","author":"Klistorner","year":"2025","journal-title":"Mult Scler J Exp Transl Clin."},{"key":"10.1016\/j.jns.2026.126191_bb0220","article-title":"Diffusivity anisotropy signature of the slowly expanding lesions predicts progression independent of relapse activity in multiple sclerosis","author":"Calvi","year":"2025","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"4","key":"10.1016\/j.jns.2026.126191_bb0225","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200253","article-title":"Central vein sign, cortical lesions, and paramagnetic rim lesions for the diagnostic and prognostic workup of multiple sclerosis","volume":"11","author":"Borrelli","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"1","key":"10.1016\/j.jns.2026.126191_bb0230","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2174\/2772432817666220412110720","article-title":"Safety and monitoring of the treatment with disease-modifying therapies (DMTs) for multiple sclerosis (MS)","volume":"18","author":"Stamatellos","year":"2023","journal-title":"Curr. Rev. Clin. Exp. Pharmacol."},{"issue":"8","key":"10.1016\/j.jns.2026.126191_bb0235","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1136\/jnnp-2012-304695","article-title":"Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: a meta-analysis of prevalence, prognosis and effect of latitude","volume":"84","author":"Dobson","year":"2013","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"10","key":"10.1016\/j.jns.2026.126191_bb0240","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1007\/s00415-025-13381-w","article-title":"Kappa free light chain index as a diagnostic and prognostic biomarker in multiple sclerosis","volume":"272","author":"Moreno-Navarro","year":"2025","journal-title":"J. Neurol."},{"issue":"8","key":"10.1016\/j.jns.2026.126191_bb0245","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s40263-021-00842-9","article-title":"The disease-modifying therapies of relapsing-remitting multiple sclerosis and liver injury: a narrative review","volume":"35","author":"Biolato","year":"2021","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.jns.2026.126191_bb0250","article-title":"Implementation of a safety program initiative for monitoring infusion disease modifying therapies for multiple sclerosis","volume":"11","author":"Roy","year":"2025","journal-title":"Mult Scler J Exp Transl Clin."},{"issue":"6","key":"10.1016\/j.jns.2026.126191_bb0255","doi-asserted-by":"crossref","first-page":"3301","DOI":"10.1007\/s00415-022-11009-x","article-title":"Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study","volume":"269","author":"Buonomo","year":"2022","journal-title":"J. Neurol."},{"key":"10.1016\/j.jns.2026.126191_bb0260","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2015-311100","article-title":"Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group","author":"McGuigan","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"3","key":"10.1016\/j.jns.2026.126191_bb0265","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S1474-4422(22)00009-6","article-title":"Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study","volume":"21","author":"Benkert","year":"2022","journal-title":"Lancet Neurol."},{"issue":"12","key":"10.1016\/j.jns.2026.126191_bb0270","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1177\/13524585221097296","article-title":"Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis","volume":"28","author":"Brune","year":"2022","journal-title":"Mult. Scler. J."},{"issue":"3","key":"10.1016\/j.jns.2026.126191_bb0275","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1001\/jamaneurol.2022.5250","article-title":"Serum glial fibrillary acidic protein compared with neurofilament light chain as a biomarker for disease progression in multiple sclerosis","volume":"80","author":"Meier","year":"2023","journal-title":"JAMA Neurol."},{"issue":"1","key":"10.1016\/j.jns.2026.126191_bb0280","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/ana.27096","article-title":"Serum glial fibrillary acidic protein and neurofilament light chain levels reflect different mechanisms of disease progression under B-cell depleting treatment in multiple sclerosis","volume":"97","author":"Benkert","year":"2025","journal-title":"Ann. Neurol."},{"issue":"24","key":"10.1016\/j.jns.2026.126191_bb0285","doi-asserted-by":"crossref","first-page":"25729","DOI":"10.18632\/aging.203790","article-title":"Factors influencing serum neurofilament light chain levels in normal aging","volume":"13","author":"Koini","year":"2021","journal-title":"Aging"},{"issue":"1","key":"10.1016\/j.jns.2026.126191_bb0290","doi-asserted-by":"crossref","first-page":"20350","DOI":"10.1038\/s41598-020-76990-7","article-title":"Renal function is associated with blood neurofilament light chain level in older adults","volume":"10","author":"Akamine","year":"2020","journal-title":"Sci. Rep."},{"issue":"12","key":"10.1016\/j.jns.2026.126191_bb0295","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16526","article-title":"Treating to target in multiple sclerosis: do we know how to measure whether we hit it?","volume":"31","author":"Bsteh","year":"2024","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jns.2026.126191_bb0300","doi-asserted-by":"crossref","DOI":"10.1177\/17562864241284372","article-title":"Beyond lines of treatment: embracing early high-efficacy disease-modifying treatments for multiple sclerosis management","volume":"17","author":"Oreja-Guevara","year":"2024","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"6","key":"10.1016\/j.jns.2026.126191_bb0305","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1007\/s00415-024-12305-4","article-title":"Early use of high-efficacy therapies in multiple sclerosis in the United States: benefits, barriers, and strategies for encouraging adoption","volume":"271","author":"Singer","year":"2024","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.jns.2026.126191_bb0310","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209444","article-title":"Using the progression independent of relapse activity framework to unveil the pathobiological foundations of multiple sclerosis","volume":"103","author":"Ciccarelli","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2026.126191_bb0315","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2025.1595929","article-title":"Progression independent of relapsing biology in multiple sclerosis: a real-word study","volume":"16","author":"Yong","year":"2025","journal-title":"Front. Neurol."},{"issue":"2","key":"10.1016\/j.jns.2026.126191_bb0320","doi-asserted-by":"crossref","DOI":"10.1111\/ene.70042","article-title":"De-escalation of disease-modifying therapy in multiple sclerosis\u2014a Danish nationwide cohort study","volume":"32","author":"Elberling","year":"2025","journal-title":"Eur. J. Neurol."},{"issue":"17","key":"10.1016\/j.jns.2026.126191_bb0325","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1212\/WNL.0000000000005347","article-title":"Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis","volume":"90","author":"Rae-Grant","year":"2018","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.jns.2026.126191_bb0330","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1093\/brain\/awq118","article-title":"The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability","volume":"133","author":"Scalfari","year":"2010","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.jns.2026.126191_bb0335","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1111\/ene.14672","article-title":"Defining the course of tumefactive multiple sclerosis: a large retrospective multicentre study","volume":"28","author":"Di Gregorio","year":"2021","journal-title":"Eur. J. Neurol."},{"issue":"6","key":"10.1016\/j.jns.2026.126191_bb0340","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001059","article-title":"Prognostic accuracy of NEDA-3 in long-term outcomes of multiple sclerosis","volume":"8","author":"Prosperini","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"6","key":"10.1016\/j.jns.2026.126191_bb0345","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200032","article-title":"Association of NEDA-4 with no long-term disability progression in multiple sclerosis and comparison with NEDA-3","volume":"9","author":"Rotstein","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"10.1016\/j.jns.2026.126191_bb0350","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211006503","article-title":"Clinico-radiologic features and therapeutic strategies in tumefactive demyelination: a retrospective analysis of 50 consecutive cases","volume":"14","author":"Vakrakou","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"8","key":"10.1016\/j.jns.2026.126191_bb0355","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1177\/13524585251335466","article-title":"Personalized treatment decision algorithms for the clinical application of serum neurofilament light chain in multiple sclerosis: a modified Delphi study","volume":"31","author":"Yaldizli","year":"2025","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.jns.2026.126191_bb0360","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2025.1575653","article-title":"Natalizumab-associated progressive multifocal leukoencephalopathy","volume":"16","author":"Glenn","year":"2025","journal-title":"Front. Neurol."},{"key":"10.1016\/j.jns.2026.126191_bb0365","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.795574","article-title":"Risk for cardiovascular adverse events associated with Sphingosine-1-phosphate receptor modulators in patients with multiple sclerosis: insights from a pooled analysis of 15 randomised controlled trials","volume":"12","author":"Zhao","year":"2021","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.jns.2026.126191_bb0370","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of Oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.jns.2026.126191_bb0375","doi-asserted-by":"crossref","first-page":"20","DOI":"10.5603\/pjnns.101995","article-title":"Recommendations of multiple sclerosis and neuroimmunology section of polish neurological society and Immuno-oncology section of polish Society of Oncology on oncological risk in patients with multiple sclerosis undergoing immunomodulatory therapy","volume":"59","author":"Ro\u015bciszewska-\u017bukowska","year":"2025","journal-title":"Neurol. Neurochir. Pol."},{"key":"10.1016\/j.jns.2026.126191_bb0380","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.ebiom.2019.07.062","article-title":"Pretreatment anti-thyroid autoantibodies indicate increased risk for thyroid autoimmunity secondary to alemtuzumab: a prospective cohort study","volume":"46","author":"Ruck","year":"2019","journal-title":"EBioMedicine"},{"issue":"2","key":"10.1016\/j.jns.2026.126191_bb0385","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1177\/13524585241303489","article-title":"DISCOntinuation of disease-modifying therapies in MS: the DISCOMS extension trial","volume":"31","author":"Corboy","year":"2025","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.jns.2026.126191_bb0390","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103225","article-title":"MENACTRIMS practice guideline for COVID-19 vaccination in patients with multiple sclerosis","volume":"56","author":"Yamout","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"13","key":"10.1016\/j.jns.2026.126191_bb0395","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1212\/WNL.0000000000008157","article-title":"Practice guideline update summary: vaccine-preventable infections and immunization in multiple sclerosis","volume":"93","author":"Farez","year":"2019","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.jns.2026.126191_bb0400","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1136\/practneurol-2018-002060","article-title":"UK consensus on pregnancy in multiple sclerosis: \u2018Association of British Neurologists\u2019 guidelines","volume":"19","author":"Dobson","year":"2019","journal-title":"Pract. Neurol."},{"issue":"2","key":"10.1016\/j.jns.2026.126191_bb0405","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/13524585231220232","article-title":"Final analysis of 379 pregnancy outcomes after exposure to dimethyl fumarate in a prospective international registry","volume":"30","author":"Hellwig","year":"2024","journal-title":"Mult. Scler. J."},{"issue":"6","key":"10.1016\/j.jns.2026.126191_bb0410","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1136\/jnnp-2023-332804","article-title":"Disease activity and neonatal outcomes after exposure to natalizumab throughout pregnancy","volume":"95","author":"Thiel","year":"2024","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"1","key":"10.1016\/j.jns.2026.126191_bb0415","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200349","article-title":"Pregnancy and infant outcomes in women with multiple sclerosis treated with ocrelizumab","volume":"12","author":"Vukusic","year":"2025","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"1","key":"10.1016\/j.jns.2026.126191_bb0420","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/pn-2022-003426","article-title":"Anti-CD20 therapies in pregnancy and breast feeding: a review and ABN guidelines","volume":"23","author":"Dobson","year":"2023","journal-title":"Pract. Neurol."},{"issue":"4","key":"10.1016\/j.jns.2026.126191_bb0425","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200110","article-title":"Multiple sclerosis disease activity and disability following cessation of fingolimod for pregnancy","volume":"10","author":"Hellwig","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"2","key":"10.1016\/j.jns.2026.126191_bb0430","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s40120-014-0020-y","article-title":"Pregnancy outcomes following maternal and paternal exposure to teriflunomide during treatment for relapsing\u2013remitting multiple sclerosis","volume":"3","author":"Kieseier","year":"2014","journal-title":"Neurol. Ther."},{"issue":"3","key":"10.1016\/j.jns.2026.126191_bb0435","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1177\/13524585221131486","article-title":"Cladribine and pregnancy in women with multiple sclerosis: the first cohort study","volume":"29","author":"Dost-Kovalsky","year":"2023","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.jns.2026.126191_bb0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102146","article-title":"Pregnancy outcomes and postpartum relapse rates in women with RRMS treated with alemtuzumab in the phase 2 and 3 clinical development program over 16 years","volume":"43","author":"Oh","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.jns.2026.126191_bb0445","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s40120-020-00201-8","article-title":"Disease-modifying drugs and family planning in people with multiple sclerosis: a consensus narrative review from the Gulf region","volume":"9","author":"Alroughani","year":"2020","journal-title":"Neurol Ther."},{"issue":"4","key":"10.1016\/j.jns.2026.126191_bb0450","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S1474-4422(22)00426-4","article-title":"Family planning considerations in people with multiple sclerosis","volume":"22","author":"Krysko","year":"2023","journal-title":"Lancet Neurol."},{"issue":"13","key":"10.1016\/j.jns.2026.126191_bb0455","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1177\/13524585241257843","article-title":"Topical review: lactation and use of DMTs in women with MS","volume":"30","author":"Hsu","year":"2024","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.jns.2026.126191_bb0460","unstructured":"European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ocrevus-epar-product-information_en.pdf. Ocrevus: current EU product information, section 4.6, Breast-feeding."},{"key":"10.1016\/j.jns.2026.126191_bb0465","unstructured":"European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/kesimpta-epar-product-information_en.pdf. Kesimpta: current EU product information, section 4.6, Lactation."},{"issue":"2","key":"10.1016\/j.jns.2026.126191_bb0470","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200371","article-title":"Assessing the risk of relapse after in vitro fertilization in women with multiple sclerosis","volume":"12","author":"Mainguy","year":"2025","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"13","key":"10.1016\/j.jns.2026.126191_bb0475","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1177\/1352458518809326","article-title":"International consensus on quality standards for brain health-focused care in multiple sclerosis","volume":"25","author":"Hobart","year":"2019","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.jns.2026.126191_bb0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanepe.2024.100891","article-title":"Consensus quality indicators for monitoring multiple sclerosis","volume":"40","author":"Voigt","year":"2024","journal-title":"The Lancet Regional Health - Europe."},{"key":"10.1016\/j.jns.2026.126191_bb0485","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.msard.2019.05.019","article-title":"Review: patient-reported outcomes in multiple sclerosis care","volume":"33","author":"D\u2019Amico","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.jns.2026.126191_bb0490","article-title":"Timely intervention, monitoring and education MATTERS in MS (TIME MATTERS in MS): development of a globally applicable quality improvement tool","volume":"8","author":"Hobart","year":"2022","journal-title":"Mult Scler J Exp Transl Clin."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X26004739?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X26004739?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:16:41Z","timestamp":1790817401000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X26004739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":98,"alternative-id":["S0022510X26004739"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2026.126191","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An integrated framework for clinical surveillance in multiple sclerosis: An evidence-informed narrative review","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2026.126191","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"126191"}}